| User's Publication |
|
21829
Wu MJ, Kondo H, Kammula AV, Shi L, Xiao Y, Dhiab S, Xu Q, Slater CJ, Avila OI, Merritt J, Kato H, Kattel P, Sussman J, Gritti I, Eccleston J, Sun Y, Cho HM, Olander K, Katsuda T, Shi DD, Savani MR, Smith BC, Cleary JM, Mostoslavsky R, Vijay V, Kitagawa Y, Wakimoto H, Jenkins RW, Yates KB, Paik J, Tassinari A, Saatcioglu DH, Tron AE, Haas W, Cahill D, McBrayer SK, Manguso RT, Bardeesy N.
Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity.
Science
2024
385(6705):eadl6173
PubMed ID: 38991060
DOI: 10.1126/science.adl6173
|
|
20228
Gamma-synuclein is a novel prognostic marker that promotes tumor cell migration in biliary tract carcinoma.
Takemura Y, Ojima H, Oshima G, Shinoda M, Hasegawa Y, Kitago M, Yagi H, Abe Y, Hori S, Fujii-Nishimura Y, Kubota N, Masuda Y, Hibi T, Sakamoto M, Kitagawa Y.
Cancer Med
2021
PubMed ID: 34245137
DOI: 10.1002/cam4.4121
|
|
20122
Hendaoui I, Lahmar A, Campo L, Mebarki S, Bichet S, Hess D, Degen M, Kchir N, Charrada-Ben Farhat L, Hefaiedh R, Ruiz C, Terracciano LM, Tucker RP, Hendaoui L, Chiquet-Ehrismann R.
Tenascin-W Is a Novel Stromal Marker in Biliary Tract Cancers.
Front Immunol
2020
11:630139
PubMed ID: 33692777
DOI: 10.3389/fimmu.2020.630139
|
|
3737
Sakamoto Y, Yamagishi S, Okusaka T, Ojima H.
Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines.
Cells
2019
8(9):1026
PubMed ID: 31484399
DOI: 10.3390/cells8091026
|
|
10759
Sakamoto Y, Yamagishi S, Tanizawa Y, Tajimi M, Okusaka T, Ojima H.
PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay.
Jpn. J. Clin. Oncol.
2018
48:396-399
PubMed ID: 29474549
DOI: 10.1093/jjco/hyy011
|
|
10290
Quintavalle C, Burmeister K, Piscuoglio S, Quagliata L, Karamitopoulou E, Sepe R, Fusco A, Terracciano LM, Andersen JB, Pallante P, Matter MS.
High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy.
Mol. Carcinog.
2017
56:2146-2157
PubMed ID: 28467612
DOI: 10.1002/mc.22671
|
|
3727
Yeung Y, Lau DK, Chionh F, Tran H, Tse JWT, Weickhardt AJ, Nikfarjam M, Scott AM, Tebbutt NC, Mariadason JM
K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.
Mol Oncol
2017
11(9):1130-1142
PubMed ID: 28544747
DOI: 10.1002/1878-0261.12078
|
|
14252
Maki T, Ikeda H, Kuroda A, Kyogoku N, Yamamura Y, Tabata Y, Abiko T, Tsuchikawa T, Hida Y, Shichinohe T, Tanaka E, Kaga K, Hatanaka K, Matsuno Y, Imai N, Hirano S.
Differential detection of cytoplasmic Wilms tumor 1 expression by immunohistochemistry, western blotting and mRNA quantification
Int J Oncol
2017
50(1):129-140.
PubMed ID: 27922671
DOI: 10.3892/ijo.2016.3786
|
|
14528
Yagai T, Matsui S, Harada K, Inagaki FF, Saijou E, Miura Y, Nakanuma Y, Miyajima A, Tanaka M.
Expression and localization of sterile alpha motif domain containing 5 is associated with cell type and malignancy of biliary tree
PLoS One
2017
12(4):e0175355
PubMed ID: 28388653
DOI: 10.1371/journal.pone.0175355
|
|
3735
Saha SK et al
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.
Cancer Discov
2016
6(7):727-39
PubMed ID: 27231123
DOI: 10.1158/2159-8290.CD-15-1442
|
|
7256
Toyota Y, Iwama H, Kato K, Tani J, Katsura A, Miyata M, Fujiwara S, Fujita K, Sakamoto T, Fujimori T, Okura R, Kobayashi K, Tadokoro T, Mimura S, Nomura T, Miyoshi H, Morishita A, Kamada H, Yoneyama H, Okano K, Suzuki Y, Masaki T.
Mechanism of gemcitabine-induced suppression of human cholangiocellular carcinoma cell growth.
Int. J. Oncol.
2015
47:1293-302
PubMed ID: 26252371
DOI: 10.3892/ijo.2015.3118
|
|
3736
Shirota T, Ojima H, Hiraoka N, Shimada K, Rokutan H, Arai Y, Kanai Y, Miyagawa S, Shibata T.
Heat Shock Protein 90 Is a Potential Therapeutic Target in Cholangiocarcinoma.
Mol Cancer Ther.
2015
14(9):1985-93
PubMed ID: 26141945
DOI: 10.1158/1535-7163.MCT-15-0069
|
|
10985
Kumai T, Ohkuri T, Nagato T, Matsuda Y, Oikawa K, Aoki N, Kimura S, Celis E, Harabuchi Y, Kobayashi H.
Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinoma
Sci Rep
2015
5:16280
PubMed ID: 26538233
DOI: 10.1038/srep16280
|
|
12541
Soejima Y, Inoue M, Takahashi Y, Uozaki H, Sawabe M, Fukusato T.
ntegrins αvβ6, α6β4 and α3β1 are down-regulated in cholangiolocellular carcinoma but not cholangiocarcinoma
Hepatol Res
2014
44(14):E320-34
PubMed ID: 24552196
DOI: 10.1111/hepr.12312
|
|
13689
Takahashi H, Ojima H, Shimizu H, Furuse J, Furukawa H, Shibata T.
Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma
Jpn J Clin Oncol
2014
44(6):570-8
PubMed ID: 24755544
DOI: 10.1093/jjco/hyu045
|
|
14930
Takahashi N, Aoyama F, Hiyoshi M, Kataoka H, Sawaguchi A.
Establishment and biological characterization of a novel cell line derived from hepatoid adenocarcinoma originated at the ampulla of Vater
Int J Oncol
2014
44(4):1139-45
PubMed ID: 24481592
DOI: 10.3892/ijo.2014.2282
|
|
18721
Morofuji N, Ojima H, Onaya H, Okusaka T, Shimada K, Sakamoto Y, Esaki M, Nara S, Kosuge T, Asahina D, Ushigome M, Hiraoka N, Nagino M, Kondo T.
Macrophage-capping protein as a tissue biomarker for prediction of response to gemcitabine treatment and prognosis in cholangiocarcinoma
J Proteomics
2012
75(5):1577-89
PubMed ID: 22155129
DOI: 10.1016/j.jprot.2011.11.030
|
|
3722
Ohashi H, Adachi Y, Yamamoto H, Taniguchi H, Nosho K, Suzuki H, Arimura Y, Imai K, Carbone DP, Shinomura Y.
Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers.
Cancer Sci
2012
103(2):252-61
PubMed ID: 22044563
DOI: 10.1111/j.1349-7006.2011.02138.x
|
|
7767
Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, Kosuge T, Yoshikawa D, Kono T, Furukawa H, Shibata T.
Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma.
Br. J. Cancer
2011
105:131-8
PubMed ID: 21673683
DOI: 10.1038/bjc.2011.199
|
|
7862
Sato J, Kimura T, Saito T, Anazawa T, Kenjo A, Sato Y, Tsuchiya T, Gotoh M.
Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.
J Hepatobiliary Pancreat Sci
2011
18:700-11
PubMed ID: 21451941
DOI: 10.1007/s00534-011-0376-7
|
|
13667
Ojima H, Yoshikawa D, Ino Y, Shimizu H, Miyamoto M, Kokubu A, Hiraoka N, Morofuji N, Kondo T, Onaya H, Okusaka T, Shimada K, Sakamoto Y, Esaki M, Nara S, Kosuge T, Hirohashi S, Kanai Y, Shibata T.
Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment
Cancer Sci
2010
101(4):882-8
PubMed ID: 20088962
DOI: 10.1111/j.1349-7006.2009.01462.x
|
|
18737
Kawase H, Fujii K, Miyamoto M, Kubota KC, Hirano S, Kondo S, Inagaki F.
Differential LC-MS-based proteomics of surgical human cholangiocarcinoma tissues
J Proteome Res
2009
8(8):4092-103
PubMed ID: 19569727
DOI: 10.1021/pr900468k
|
|
3705
Oka T, Yamamoto H, Sasaki S, Ii M, Hizaki K, Taniguchi H, Adachi Y, Imai K, Shinomura Y.
Overexpression of beta3/gamma2 chains of laminin-5 and MMP7 in biliary cancer.
World J Gastroenterol
2009
15(31):3865-73
PubMed ID: 19701966
DOI: 10.3748/wjg.15.3865
|
|
6410
Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y.
Is parainfluenza virus a threatening virus for human cancer cell lines?
Hum Cell
2009
22(3):81-4
PubMed ID: 19624309
DOI: 10.1111/j.1749-0774.2009.00071.x
|
|
18693
Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M, Hirohashi S.
Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer
Gastroenterology
2008
135(4):1358-1368
PubMed ID: 18692501
DOI: 10.1053/j.gastro.2008.06.082
|
Back
Top
CELL BANK Website
